We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.
Thirteen clinical trials of repurposed drugs have been undertaken to build a portfolio of therapeutic options for COVID-19 patients, said the Minister.
A larger Phase III trial involving several thousand people is expected to begin in August, said Russian Direct Investment Fund (RDIF) head Kirill Dmitriev.
The COVID-19 pandemic cannot be controlled by the herd immunity strategy and vaccines will be the key to ultimately tackling the virus, said Zhong Nanshan, a prominent Chinese expert in respiratory diseases.